Clinical Trial Update: BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) [Phase 2]

View source ↗

Summary

Phase 2 trial update on BRAF/MEK inhibition for relapsed/refractory multiple myeloma with BRAFV600E/K mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: University of Heidelberg Medical Center | Conditions: Relapsed or Refractory Multiple Myeloma, Patients With BRAFV600 E or BRAFV600K Mutation | Phase 2 | Status: COMPLETED